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Success of kidney transplantation in oxalosis is unrelated to residual
hepatic enzyme activity. We evaluated hepatic alanine glyoxylate ami-
notransferase (AGT) activity in percutaneous hepatic biopsy material
obtained from four children with long-term renal allograft function
following transplantation for primary hyperoxaluria type 1 (PH 1). The
study was performed to determine whether these successes had oc-
curred because relatively high residual levels of AGT activity had
introduced a selection bias. The children ranged from seven months to
eight years at transplant and are currently well 7 to 11 years later, with
no oxalate deposition on repeated allograft biopsies and creatinine
clearances of 80 to 128 mI/min/! .73 m2. AGT activity ranged from 0 to
13.8%, and in two of three patients with detectable levels the AGT was
in mitochondrja rather than peroxisomes. These results indicate that
long-term renal allograft success can occur in spite of severe AGT
deficiency. Thus, the therapeutic choice of kidney alone versus com-
bined kidney-liver transplant cannot currently be made by measuring
residual hepatic AGT in PH 1. Kidney transplant alone remains a
reasonable initial therapeutic alternative for patients with recent onset
of renal insufficiency due to PH 1.
Primary hyperoxaluria type 1 (PH 1) is an autosomal reces-
sive disorder caused by a deficiency of the hepatic peroxisomal
enzyme alanine:glyoxylate aminotransferase (AGT) [1]. Pa-
tients with PH 1 manifest increased synthesis and urinary
excretion of oxalate, urolithiasis, and a high risk of a gradual
reduction in renal function leading to end-stage renal disease
(ESRD) in late childhood and early adulthood [2]. A more
severe, albeit rare, form of the disease is encountered in infants
presenting in ESRD due to nephrocalcinosis with no antecedent
stone disease [2—7]. Since the oxalate removal rate by dialysis is
less than its endogenous production rate, calcium oxalate
continues to accumulate in the body of PH 1 patients with
ESRD, eventually leading to systemic oxalosis and the patient's
demise [8—10].
Although renal transplantation was introduced in the 1970's
as a treatment for ESRD in PH 1 patients, a high failure rate
with this procedure has been reported by most transplantation
centers [11]. Recent data from the European Dialysis and
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Transplantation Association (EDTA) registry summarizing 20
years experience with kidney transplantation for PH 1, cites a
three-year graft survival of 23% for patients receiving a living
related donor and 18% cadaveric donors. The more recent
results in the EDTA series are only slightly better [12].
Due to the high failure rate of kidney transplantation, and
because the basic biochemical defect (AGT deficiency) is in the
liver, some centers now advocate liver transplantation (most
often combined with kidney transplantation) as the procedure
of choice for PH 1 patients with ESRD [13—19].
Some of us have previously reported long-term patient sur-
vival with excellent graft function in patients who received
kidney transplants for ESRD secondary to presumed PH 1 [20].
All the patients had presented with ESRD and therefore defin-
itive diagnosis by urine/plasma oxalate measurement had not
been possible. The relatively high success rate in these patients
has been attributed to early transplantation, aggressive pre-
transplantation dialysis and the use of a medical protocol
previously outlined in detail [20]. More recently we have
reported our long-term follow-up of eight PH 1 children treated
with renal transplantation. Four of these eight patients have
now survived 6.5 to 10.5 years after renal transplantation and
still maintain good renal function with no evidence of renal
oxalate deposition on renal allograft biopsies [21]. In an attempt
to determine whether the successful long-term outcome of renal
transplantation was the result of clinical management or some
intrinsic (genetic) characteristic of their disease, we have deter-
mined the degree of hepatic AGT deficiency in these patients.
Methods
Patients
The four patients included in this study were selected from
eight previously reported patients because of their long-term
success following kidney transplantation for PH 1. The other
four patients are dead [21].
All presented with ESRD secondary to nephrocalcinosis
without antecedent urolithiasis (Table 1). All had extrarenal
oxalate deposits. The four were treated according to a previ-
ously described protocol: early transplantation and aggressive
pre-transplantation dialysis. Following transplantation the pa-
tients were maintained on high fluid intake, vitamin B6, mag-
nesium, orthophosphate supplementation and thiazide diuretics
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Table 1. Patient characteristics
Patient
Age
ESRDb
in months
TX-i TX-2
Reason for 1st
allograft failure
Current status Hepatic AGT
Follow up
since last TX
months
GFR
mI/mm/I .73 m2
Allograft
oxalosis
Age at
liver biopsy
months
Enzyme
activity CRM
Subcellular
localization
i
2
3
4
78
3.5
2.0
3.0
96
7
7
16
—
30
—
24
—
Pneumoccocal sepsis
—
Sepsis, dehydration
120
84
96
72
97
101
80
128
none
none
none
none
204
108
96
84
0
5.6
9.1
13.8
—
+
+
+++
—
P + M
—
M
AGT was corrected for crossover from glutamate glyoxylate aminotransferase for patient #1. For patients #2, 3 and 4, the crossover could only
be estimated. AGT activity is expressed as % of the mean of the control value (Danpure and Jennings 1988). Abbreviations are: CRM, presence
of immunologically cross reactive material (+ + + + normal; — undetectable); P, peroxisomal; M, mitochondrial; TX, transplantation; GFR,
glomerular filtration rate determined by creatinine clearance.
a In a graft biopsy 60 months following transplantationb All patients anuric or severely oliguric at presentation
[20]. All had bilateral nephrectomy and splenectomy at or
before transplantation. All grafts were from living related
donors. Cyclosporine was not available for use at the time these
transplants were performed and immunosuppression included
azathioprine (Imuran), prednisone, and, for induction, 14 days
of antilymphoblast globulin.
Patients #2 and #4 required retranspiantation (Table 1). The
first allograft in patient #2 failed 20 months post-transplantation
following an episode of overwhelming pneumococcal sepsis
with shock and cerebral vascular thrombosis and infarction.
Failure of the primary graft in patient #4 occurred three months
post-transplantation and was associated with small bowel ob-
struction and dehydration, E. coli sepsis, and urinary tract
infection, and cytomegalovirus infection.
All four patients are currently well 7 to 11 years following
transplantation with creatinine clearance of 80 to 128 mi/minI
1.73 m2 (Table 1). There was no evidence of calcium oxalate or
calcium phosphate deposition in the kidney.
Study protocol
For the purpose of this study all four patients were admitted
to the Clinical Research Center at the University of Minnesota
(U of M) to participate in a protocol approved by the Committee
for the use of Human Subjects in Research at the U of M. All
four patients underwent percutaneous kidney and liver biop-
sies. All but one patient had adequate kidney and liver tissue for
analysis. In patient #3 the liver specimen was inadequate for
immunoelectron microscopy.
Laboratory methods
Glomerular filtration rate (GFR) was assessed using creati-
nine clearance. Serum and urinary creatinine were measured
using the Jaffè method [221.
To make a definitive enzymological diagnosis in the patients
under this study, percutaneous needle liver biopsies were
performed. Portions of each biopsy were fixed in 1% glutaral-
dehyde and used for the determination of the intracellular
localization of AGT by post-embedding protein-A gold immu-
noelectron microscopy [23]. The remainder of each biopsy was
frozen until required for the determination of AGT enzyme
assay using the macro-spectrophotometric method in patient #1
[24] and the micro-radioactive electrophoretic method [25] for
patients #2 through 4. The presence of immunoreactive AGT
was established by SDS-PAGE/Western blotting [251.
Results
All four patients in the present study had marked deficiencies
in hepatic AGT activity (0 to 13.8%) and immunoreactive
protein (Table 1). These data confirm the diagnosis of PH 1. In
addition, in two of the three patients with detectable levels of
AGT, the enzyme was found localized within the mitochondria
rather than in the peroxisomes, but it could not be studied in
one. In patient #4 the AGT was >90% within the mitochondria,
while in patient #2 —50% of the gold particles were in mito-
chondria and the remaining particles in peroxisomes. In the
single patient with 0% hepatic AGT activity no immune reactive
AGT was detected.
Confirming earlier studies on these patients, and as stated
above, all patients have excellent graft function as evidenced by
normal GFR's and no evidence of calcium oxalate or calcium
phosphate deposition in the allograft (Table 1).
Discussion
Four of eight of the children with PH 1 transplanted at our
center have achieved long-term renal graft function. One might
speculate that these successes could have represented a selec-
tion bias because these patients happened to have a higher level
of hepatic AGT than most PH 1 patients with renal failure.
However, the current study clearly shows that our four long-
term survivors all had severe enzyme defects associated in
three with aberrant localization of the enzyme, thus establishing
the diagnosis of PH 1 and ruling out secondary causes of
hyperoxaluria, and primary hyperoxaluria type 2 [26—28]. The
small number of patients does not permit us to determine
whether the long term success of kidney transplantation may be
related to a higher percent of patients with residual AGT
activity than has been previously reported elsewhere (24/59 vs.
3/4 in our series) [27]. However, it is reasonable to conclude
from our results that neither severe clinical presentation with
renal failure in infancy or early childhood nor complete absence
of hepatic AGT enzyme activity precludes successful kidney
transplantation.
The recent association of PH 1 with defects, both genotypic
[29, 30] and phenotypic [1], in AGT coupled with the immediate
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correction of urinary oxalate overexcretion following liver
transplantation [15] suggest that hepatic AGT is an important
determinant of the level of endogenous oxalate production.
However, in patients with PH 1, the relationship between
hepatic enzyme level and location with the renal filtered load of
oxalate or with the rate of development of renal injury is
complex and poorly understood [28, 31, 32]. In accord with this
is our experience that the only patient in our series with total
absence of AGT (patient #1), had the mildest clinical course
with ESRD, presenting at six years of age, and did not require
retranspiantation. Further, variability in the clinical course of
patients with similar AGT levels suggests that residual AGT
activity may be only one of several genetic and environmental
factors dictating the natural history of PH 1. Such factors may
include: the activity of other enzymes capable of affecting
oxalate synthesis, variation in urinary solubility of oxalate,
nutrition, and climate [28]. These unknown factors, as well as
variables such as total body oxalate load and clinical manage-
ment, may influence renal allograft outcome.
It is therefore not surprising that the current study does not
support the concept that hepatic AGT activity can be used as
the sole means for selecting the transplant procedure of choice
in the individual PH 1 patient. Thus, there is currently no single
factor capable of determining this decision. It is possible that
careful study of a larger number of patients could elucidate a
clearer decision making paradigm. However, this will be a slow
task considering the rarity of the disease, the high mortality rate
with all current treatment modalities, and variations in manage-
ment approaches between centers.
The present study confirms the value of kidney transplanta-
tion for some patients with ESRD due to PH 1. Recently
reported short term results of combined liver-kidney transplan-
tation in adults are similar to ours with kidney transplantation
alone [18]. Our experience with kidney transplantation both in
adults [20] and children [21] indicates that the loss of renal
allograft in PH 1 patients is a two stage process requiring first a
reduction in graft function (rejection, obstruction, dehydration,
etc). followed later by diffuse oxalate deposition in the kidney.
The majority of such events occur during the first post-trans-
plant year when the oxalate burden (consisting of endogenous
production and mobilization of tissue stores) is at its peak. Late
complications are rare as evidenced by the stable late post-
transplant course of our patients. Thus, the major advantage of
liver transplantation is in reducing the oxalate load during this
critical period rather than in the ultimate cure of a disease that
may take two to three decades prior to reaching renal failure
(probably longer if adequately treated). We would therefore
reserve liver transplantation for patients with clinical evidence
of markedly increased oxalate tissue stores, and/or patients
managed by regular dialysis for more than one year. A loss of a
renal allograft would serve as an indication for liver transplan-
tation only if it occurred in spite of optimal management. Other
factors which may favor liver transplantation would be high
oxalate production rate (evidenced by high oxlate excretion rate
and/or tissue oxalate accretion [33]) and a rapid course from
presentation to ESRD. Kidney transplantation should be per-
formed prior to renal failure [34]. These recommendations will
need to be reviewed when long-term follow-up of liver trans-
plantation results in PH 1 become available and more experi-
ence with early kidney transplantation is obtained.
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